Tags

Type your tag names separated by a space and hit enter

Cationic drugs and COVID-19.
Int J Immunopathol Pharmacol. 2020 Jan-Dec; 34:2058738420966078.IJ

Abstract

Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19.

Authors+Show Affiliations

Department of Food, Environmental and Nutritional Sciences, Università degli Studi di Milano, Milan, Italy. Retired Professor.Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Milan, Italy.Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Milan, Italy.Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Milan, Italy.

Pub Type(s)

Letter

Language

eng

PubMed ID

33045858

Citation

Brenna, Oreste Vittore, et al. "Cationic Drugs and COVID-19." International Journal of Immunopathology and Pharmacology, vol. 34, 2020, p. 2058738420966078.
Brenna OV, Torretta S, Pignataro L, et al. Cationic drugs and COVID-19. Int J Immunopathol Pharmacol. 2020;34:2058738420966078.
Brenna, O. V., Torretta, S., Pignataro, L., & Di Berardino, F. (2020). Cationic drugs and COVID-19. International Journal of Immunopathology and Pharmacology, 34, 2058738420966078. https://doi.org/10.1177/2058738420966078
Brenna OV, et al. Cationic Drugs and COVID-19. Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420966078. PubMed PMID: 33045858.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cationic drugs and COVID-19. AU - Brenna,Oreste Vittore, AU - Torretta,Sara, AU - Pignataro,Lorenzo, AU - Di Berardino,Federica, PY - 2020/10/13/entrez PY - 2020/10/14/pubmed PY - 2020/10/21/medline KW - COVID-19 KW - cationic drugs KW - emergency KW - infection KW - pandemic SP - 2058738420966078 EP - 2058738420966078 JF - International journal of immunopathology and pharmacology JO - Int J Immunopathol Pharmacol VL - 34 N2 - Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19. SN - 2058-7384 UR - https://www.unboundmedicine.com/medline/citation/33045858/Cationic_drugs_and_COVID_19_ L2 - https://journals.sagepub.com/doi/10.1177/2058738420966078?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -